Literature DB >> 22580916

Carriage of Clostridium difficile in outpatients with irritable bowel syndrome.

Evelyn M Clayton1,2, Mary C Rea1,2, Fergus Shanahan3,1, Eamonn M M Quigley3,1, Barry Kiely4, R Paul Ross1,2, Colin Hill5,1.   

Abstract

Irritable bowel syndrome (IBS) is a common, typically chronic and sometimes disabling gastrointestinal condition of uncertain aetiology. Recently, a variety of links to gastrointestinal infections have been described including the onset of IBS following exposure to enteric pathogens and an apparent predisposition to gastrointestinal infection. The prevalence of Clostridium difficile in a population of IBS outpatients (n = 87) in the absence of established risk factors for the acquisition of C. difficile infection was examined. Overall, 5.7 % of patients (n = 5) carried culturable C. difficile and 4.6 % (n = 4) of isolates were toxigenic, belonging to toxinotype group 0, compared with 1.1 % (n = 1) for the healthy control group (n = 88). These isolates were members of toxigenic PCR ribotype groups 005 and 050 (IBS group) and 062 (control group) and were identified further as three individual strains by PFGE. Although no significant difference was observed between IBS patients and healthy volunteers, these findings support the concept that a subpopulation of IBS patients may be susceptible to gastrointestinal infection.

Entities:  

Mesh:

Year:  2012        PMID: 22580916     DOI: 10.1099/jmm.0.040568-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  7 in total

1.  Regulation and Anaerobic Function of the Clostridioides difficile β-Lactamase.

Authors:  Brindar K Sandhu; Adrianne N Edwards; Sarah E Anderson; Emily C Woods; Shonna M McBride
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Clostridium difficile-related postinfectious IBS: a case of enteroglial microbiological stalking and/or the solution of a conundrum?

Authors:  Gabrio Bassotti; Lara Macchioni; Lanfranco Corazzi; Pierfrancesco Marconi; Katia Fettucciari
Journal:  Cell Mol Life Sci       Date:  2017-12-28       Impact factor: 9.261

3.  Detection of Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease is unrelated to the presence of single nucleotide polymorphisms rs2241880 (ATG16L1) and rs10045431 (IL12B).

Authors:  James P Dalton; Alan Desmond; Fergus Shanahan; Colin Hill
Journal:  Med Microbiol Immunol       Date:  2014-02-13       Impact factor: 3.402

4.  Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.

Authors:  M Pimentel; B D Cash; A Lembo; R A Wolf; R J Israel; P Schoenfeld
Journal:  Dig Dis Sci       Date:  2017-06-06       Impact factor: 3.199

5.  Novel Testing Enhances Irritable Bowel Syndrome Medical Management: The IMMINENT Study.

Authors:  Kelly Parsons; Julius Goepp; Bryan Dechairo; Elizabeth Fowler; Nathan Markward; Patrick Hanaway; Teresa McBride; Darryl Landis
Journal:  Glob Adv Health Med       Date:  2014-05

6.  Frequency of abnormal fecal biomarkers in irritable bowel syndrome.

Authors:  Julius Goepp; Elizabeth Fowler; Teresa McBride; Darryl Landis
Journal:  Glob Adv Health Med       Date:  2014-05

7.  Comparison of the antibacterial activity of essential oils and extracts of medicinal and culinary herbs to investigate potential new treatments for irritable bowel syndrome.

Authors:  Aiysha Thompson; Dilruba Meah; Nadia Ahmed; Rebecca Conniff-Jenkins; Emma Chileshe; Chris O Phillips; Tim C Claypole; Dan W Forman; Paula E Row
Journal:  BMC Complement Altern Med       Date:  2013-11-28       Impact factor: 3.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.